IRIS
RIMASSA, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.623
AS - Asia 7.814
EU - Europa 2.468
SA - Sud America 1.645
AF - Africa 348
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 2
Totale 23.936
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.369
SG - Singapore 4.843
BR - Brasile 1.362
CN - Cina 1.227
VN - Vietnam 771
FI - Finlandia 454
IT - Italia 425
IE - Irlanda 334
DE - Germania 306
HK - Hong Kong 217
FR - Francia 208
NG - Nigeria 206
IN - India 170
GB - Regno Unito 169
CA - Canada 154
NL - Olanda 132
AR - Argentina 110
BD - Bangladesh 102
SE - Svezia 88
TR - Turchia 80
MX - Messico 67
IQ - Iraq 62
RU - Federazione Russa 56
JP - Giappone 52
ID - Indonesia 48
ZA - Sudafrica 44
CL - Cile 41
EC - Ecuador 41
BE - Belgio 38
PL - Polonia 37
IL - Israele 36
ES - Italia 35
AT - Austria 34
UA - Ucraina 33
CO - Colombia 32
PK - Pakistan 28
SA - Arabia Saudita 26
UZ - Uzbekistan 24
MA - Marocco 22
AU - Australia 21
VE - Venezuela 21
EG - Egitto 18
PH - Filippine 16
CZ - Repubblica Ceca 15
LT - Lituania 15
PY - Paraguay 15
AZ - Azerbaigian 14
DZ - Algeria 14
KE - Kenya 14
PT - Portogallo 12
IR - Iran 11
NP - Nepal 11
UY - Uruguay 11
JO - Giordania 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
PE - Perù 9
BY - Bielorussia 8
CH - Svizzera 8
EU - Europa 8
KZ - Kazakistan 8
KR - Corea 7
MY - Malesia 7
ET - Etiopia 6
GR - Grecia 6
HR - Croazia 6
JM - Giamaica 6
KG - Kirghizistan 6
RO - Romania 6
AL - Albania 5
BG - Bulgaria 5
CR - Costa Rica 5
DO - Repubblica Dominicana 5
MD - Moldavia 5
RS - Serbia 5
HU - Ungheria 4
LB - Libano 4
LV - Lettonia 4
NI - Nicaragua 4
OM - Oman 4
PA - Panama 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BH - Bahrain 3
HN - Honduras 3
KH - Cambogia 3
ML - Mali 3
NO - Norvegia 3
PS - Palestinian Territory 3
AQ - Antartide 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
GA - Gabon 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
Totale 23.911
Salva come PNG Salva come JPEG
Città #
Singapore 2.133
Dallas 1.729
Wilmington 1.287
Chandler 1.285
Ashburn 775
The Dalles 632
Shanghai 559
San Mateo 477
San Jose 476
Helsinki 454
Ann Arbor 394
Dublin 333
Beijing 298
Ho Chi Minh City 274
New York 267
Lawrence 253
Princeton 252
Boardman 243
Leawood 232
Benin City 205
Hong Kong 197
Hanoi 178
Paris 146
Milan 135
Amsterdam 110
Fairfield 108
Woodbridge 108
São Paulo 103
Los Angeles 88
London 81
Toronto 76
Santa Clara 75
Phoenix 66
Columbus 58
Seattle 51
Council Bluffs 50
Orem 44
San Diego 42
Rio de Janeiro 41
Kocaeli 39
Naples 39
Montreal 37
Belo Horizonte 36
Brussels 35
Falkenstein 35
Tokyo 35
Da Nang 34
Brasília 32
Chennai 32
Haiphong 32
Pune 32
Abbiategrasso 31
Munich 31
Redwood City 31
Warsaw 31
Assago 28
Norwalk 27
Salvador 27
Brooklyn 24
Mexico City 23
Baghdad 22
Curitiba 22
Tashkent 22
Hải Dương 20
Porto Alegre 20
Dhaka 19
Johannesburg 19
Campinas 18
Guayaquil 18
San Francisco 18
Chicago 17
Frankfurt am Main 17
Manchester 17
Atlanta 16
Boston 16
Houston 16
Moscow 16
Guarulhos 15
Redmond 15
Baku 14
Jeddah 14
Ninh Bình 14
Ribeirão Preto 14
St Louis 14
Andover 13
Biên Hòa 13
Jakarta 13
Milwaukee 13
Monmouth Junction 13
Stockholm 13
Fortaleza 12
Mumbai 12
Santiago 12
Denver 11
Istanbul 11
New Delhi 11
Quito 11
São Bernardo do Campo 11
Thái Bình 11
Xi'an 11
Totale 15.590
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis 308
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment 217
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 174
Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report 163
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 156
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 153
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 148
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 136
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 131
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 127
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 122
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 119
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 118
Tivantinib for hepatocellular carcinoma 115
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 114
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 113
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 112
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 111
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 110
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 110
Biomarkers in Hepatocellular Carcinoma-Letter 109
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 109
COVID-19 and liver cancer clinical trials: not everything is lost 107
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 105
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 105
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 105
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 103
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 103
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 103
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 101
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 101
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 100
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 99
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 99
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 97
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 96
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 95
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 94
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 94
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 93
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 93
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 92
Prognostic value of the immune-related transcriptome in biliary tract cancers 91
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 91
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 91
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 90
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 90
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 90
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 89
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 89
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 88
Cabozantinib for the treatment of hepatocellular carcinoma 88
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 88
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 88
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 87
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 87
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 87
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 87
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 86
Characterisation of the immune-related transcriptome in resected biliary tract cancers 86
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 85
From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology 84
Shaping the landscape of immune oncology in hepatocellular carcinoma 84
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 84
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 84
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 84
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 83
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 83
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 83
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 83
Reply to Y. Pointreau et al 83
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 83
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 83
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 82
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 82
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 82
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 82
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 81
Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells 81
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 81
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 81
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 80
Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer 80
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 79
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 79
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 79
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 79
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 78
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 78
Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma 78
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 78
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers 78
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 77
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 77
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells 77
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 77
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 76
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 76
Nurses and health care assistants: Evaluation of attitude towards the care of patients who are terminally ill with cancer. 76
Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer 76
Totale 9.869
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.615
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021596 0 0 0 0 0 0 0 0 0 314 33 249
2021/20221.504 61 43 20 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20242.440 161 251 455 89 76 341 161 127 36 53 278 412
2024/20253.714 121 62 29 57 75 432 284 337 580 794 424 519
2025/202610.476 1.462 1.455 1.081 1.192 339 527 2.794 506 535 585 0 0
Totale 24.458